PREPARATION AND IN-VITRO EVALUATION OF LAMIVUDINE MATRIX TABLETS FOR ORAL SUSTAINED RELEASE DRUG DELIVERY SYSTEM USING METHOCEL K15M CR POLYMER

The present work reports the learning of different proportion of Lamivudine: Methocel K15M, which will, describe the effect of polymer proportion and diluent on the drug release mechanism. The authors used Lamivudine, an anti-HIV agent as the model drug to evaluate its release characteristics from d...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutical sciences and research Vol. 6; no. 1; p. 164
Main Authors Chaurasiya, Amit Kumar, Ansary, Johura, Rahaman, Md Sofiqur, Alam, Md Ershad
Format Journal Article
LanguageEnglish
Published 01.01.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present work reports the learning of different proportion of Lamivudine: Methocel K15M, which will, describe the effect of polymer proportion and diluent on the drug release mechanism. The authors used Lamivudine, an anti-HIV agent as the model drug to evaluate its release characteristics from different matrices. Direct compression method used for preparation of Matrix tablets of Lamivudine using Methocel K15M CR polymer. In vitro release studies were performed using US Pharmacopeia type 1 apparatus in 900 ml of pH 6.8 phosphate buffer at 100 rpm for 8 hours. Surface properties of matrices are determined by using Scanning Electron Microscopy. Statically substantial difference found among the drug release outline form different formulations. When polymer used as lower content, the rate of drug release evaluated while polymer content in higher range in the matrix release extended > 8 hours due to increased tortuosity and decreased porosity. The release mechanism explored and explained with zero order, first order, Higuchi and Korsmeyer and Hixon-Crowell equations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0975-8232
DOI:10.13040/IJPSR.0975-8232.6(1).164-71